Technical Analysis for IMMX - Immix Biopharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Spinning Top | Other | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.96% | |
| NR7 | Range Contraction | 0.96% | |
| Narrow Range Bar | Range Contraction | 0.96% | |
| Fell Below 20 DMA | Bearish | -3.21% | |
| Bollinger Band Squeeze | Range Contraction | -3.21% | |
| Crossed Above 20 DMA | Bullish | -8.66% | |
| Bollinger Band Squeeze | Range Contraction | -8.66% |
| Alert | Time |
|---|---|
| Possible NR7 | 1 day ago |
| Fell Below Previous Day's Low | 2 days ago |
| Down 1% | 2 days ago |
| 60 Minute Opening Range Breakdown | 2 days ago |
| Up 2% | 2 days ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/28/2024
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. It is developing IMX-110 that is in Phase Ib/IIa clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. The company has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase Ib clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc. was incorporated in 2012 and is based in Los Angeles, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Ulcerative Colitis Sarcoma Abdominal Pain Crohn's Disease Soft Tissue Sarcoma
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Ulcerative Colitis Sarcoma Abdominal Pain Crohn's Disease Soft Tissue Sarcoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.75 |
| 52 Week Low | 1.55 |
| Average Volume | 128,499 |
| 200-Day Moving Average | 3.54 |
| 50-Day Moving Average | 2.48 |
| 20-Day Moving Average | 2.25 |
| 10-Day Moving Average | 2.25 |
| Average True Range | 0.22 |
| RSI (14) | 41.86 |
| ADX | 19.32 |
| +DI | 16.31 |
| -DI | 22.67 |
| Chandelier Exit (Long, 3 ATRs) | 2.04 |
| Chandelier Exit (Short, 3 ATRs) | 2.60 |
| Upper Bollinger Bands | 2.47 |
| Lower Bollinger Band | 2.02 |
| Percent B (%b) | 0.19 |
| BandWidth | 20.00 |
| MACD Line | -0.08 |
| MACD Signal Line | -0.08 |
| MACD Histogram | 0.0016 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.26 | ||||
| Resistance 3 (R3) | 2.26 | 2.20 | 2.24 | ||
| Resistance 2 (R2) | 2.20 | 2.17 | 2.21 | 2.23 | |
| Resistance 1 (R1) | 2.16 | 2.14 | 2.18 | 2.16 | 2.22 |
| Pivot Point | 2.10 | 2.10 | 2.12 | 2.11 | 2.10 |
| Support 1 (S1) | 2.06 | 2.07 | 2.08 | 2.06 | 2.00 |
| Support 2 (S2) | 2.00 | 2.04 | 2.01 | 1.99 | |
| Support 3 (S3) | 1.96 | 2.00 | 1.99 | ||
| Support 4 (S4) | 1.96 |
